ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
https://doi.org/10.20996/1819-6446-2009-5-6-55-58
Abstract
Data of evidence based medicine which confirm efficacy of acetylsalicylic acid (ACA) in cardiologic practice are presented. The special attention is given to generic drugs of ACA. Their application has increased essentially recently. Some of generics are comparable with original drugs on clinical efficacy but have economic advantages.
About the Authors
N. A. Dmitrieva
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Russian Federation
Petroverigsky per. 10, Moscow, 101990
S. N. Tolpygina
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Russian Federation
Petroverigsky per. 10, Moscow, 101990
References
1. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827-30.
2. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343(12):834-9.
3. McDowell A., Engel A., Massey J.T., Maurer K. Plan and operation of the Second National Health and Nutrition Examination Survey, 1976-1980. Vital Health Stat 1. 1981;(15):1-144.
4. Smith S.C.Jr.,Allen J., Blair S.N. et al.АНА/АСС; NationalHeart, Lung and Blood Institute.АНА/АСС guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation 2006;113(19):2363-72.
5. Juul-Möller S., Edvardsson N., Jahnmatz B., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.. Lancet 1992;340(8833):1421-5.
6. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002;324(7329):71–86.
7. Berger J.S., Brown D.L., Becker R.C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121(1):43-9.
8. Baigent C., Blackwell L., Collins R. et al. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373(9678):1849-60.
9. Serebruany V.L., Steinhubl S.R., Berger P.V. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95(10):1218-22
10. Кучерявая Н.Г., Ермакова О.В., Кокурина Е.В. и др. Антиагрегантная эффективность и переносимость буккальной и пероральной кишечнорастворимой форм ацетилсалициловой кислоты. Профилактика заболеваний и укрепление здоровья 2008;(5):35-8
11. Kelly J.P., KaufmanD.W.,Jurgelon J.M. et al. Risk of aspirin-associated major upper gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348(9039):1413-6.
12. Белолипецкий Н.А., Толпыгина С.Н., Литинская О.А. и др. Дезагрегантная эффективность и переносимость оригинального препарата «Аспирин кардио» и его дженерика «Ацекардола» у больных артериальной гипертензией 1-2-ой степени. Рациональная Фармакотерапия в Кардиологии 2008;(1):19-24
13. Cryer B. Gastrointestinal safety oflow-dose aspirin. Am JManag Care2002;8(22Suppl):S701-8.
14. Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-17.
Review
For citations:
Dmitrieva N.A., Tolpygina S.N. ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS. Rational Pharmacotherapy in Cardiology. 2009;5(6):55-58. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-6-55-58
Views:
779
Email this article 